Mesalazine initiates an anti-oncogenic β-catenin / MUCDHL negative feed-back loop in colon cancer cells by cell-specific mechanisms

Abstract excerpt

Chronic inflammation associated with intestinal architecture and barrier disruption puts patients with inflammatory bowel disease (IBD) at increased risk of developing colorectal cancer (CRC). Widely used to reduce flares of intestinal inflammation, 5-aminosalicylic acid derivatives (5-ASAs) such as mesalazine appear to also exert more direct mucosal healing and chemopreventive activities against CRC. The...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Digestive system and related health
• Share to Genetic factors in colorectal cancer
• Share to Wnt/β-catenin signaling in development and cancer